Total Utang marang Modal Artiva Biotherapeutics, Inc. (ARTV)

Artiva Biotherapeutics, Inc. - logo grafis emiten ARTV

Artiva Biotherapeutics, Inc. (ARTV) adheres to bioethics and sustainability principles in the development of cell therapies by optimizing waste disposal. High barriers to entry in the industry are maintained by gene modification patents and the complexity of mass-producing biologics. Current price action on GURU.Markets, where the total debt-to-equity ratio stands at 0.03, confirms the expansion of allogeneic cancer therapies through the attraction of investment and B2B alliances.

Artiva Biotherapeutics Inc. (ARTV): Rasio Utang marang Ekuitas saka 20.07.2024 nganti 02.11.2026

Rincian metrik lan analitis perusahaan Artiva Biotherapeutics (ARTV)

- rega saham lan konsensus proyeksi valuasi:
Rega saham Artiva Biotherapeutics Inc.|ARTV - Target konsensus
- rincian kapitalisasi pasar:
Kapitalisasi pasar Artiva Biotherapeutics|ARTV - Nilai Perusahaan
- indikator kapitalisasi buku:
Aset Bersih saben Siji Saham Artiva Biotherapeutics|ARTV - Kapitalisasi Akuntansi|Rasio Kapitalisasi Pasar marang Nilai Buku artivabio.com|ARTV - Gunggung Aset Perusahaan
- rincian utang lan likuiditas:
Total Utang marang Modal Artiva Biotherapeutics, Inc.|ARTV - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas Artiva Biotherapeutics Inc.|ARTV - Kewajiban utang agregat|Utang marang nilai buku Artiva Biotherapeutics|ARTV - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Artiva Biotherapeutics|Indikator likuiditas cepet artivabio.com
- data bathi resik lan rasio valuasi:
ARTV - Bathi resik
Pambiji fundamental perusahaan:Artiva Biotherapeutics, Inc.
Produk dadi Artiva Biotherapeutics Inc.

Analyzing the debt leverage history of Artiva Biotherapeutics, Inc. (ARTV), an investor assesses the total liabilities-to-equity ratio, which determines the business's degree of dependence on borrowed funds. For an NK-cell developer with a long patenting cycle, this indicator is critical: excessive debt load may limit investments in product scaling, creating risks when implementing a strategy of technological dominance.

Analisis pesaing Artiva Biotherapeutics, Inc.

ONC (BeiGene) - Total Utang marang Modal|Rasio Total Utang marang Ekuitas Halozyme Therapeutics, Inc. (HALO)|Total Utang marang Modal RVMD|Total Utang marang Modal Ascentage Pharma Corp (AAPG)|Utang marang Ekuitas CG Oncology, Inc. CGON|URGN: Rasio Utang marang Ekuitas|Bicara Therapeutics - Total Utang marang Modal|Personalis Inc (PSNL) - Rasio Total Utang marang Ekuitas|ERAS: Total Utang marang Modal|Utang marang Modal Delcath Corp (DCTH)|Utang marang Ekuitas Y-mAbs Therapeutics|AURA: Rasio Kabeh Utang marang Dana Pribadi|Rasio Total Utang marang Ekuitas CADL (Candel Therapeutics)|ARAY (Accuray Inc) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal SLS (SELLAS Life Sciences Group)|ACTU - Rasio Total Utang marang Ekuitas|CTOR: Rasio Total Utang marang Ekuitas|HURA - Total Utang marang Modal|Protara Therapeutics, Inc. (TARA) - Utang marang Ekuitas|Fate Therapeutics Inc - Rasio Kabeh Utang marang Dana Pribadi|WHWK (Aadi Bioscience, Inc.) - Total Utang marang Modal|Utang marang Modal TScan TCRX|Total Utang marang Modal CSBR|Total Utang marang Modal xbiotech.com (XBIT)|Utang marang Ekuitas CEL-SCI CVM|Rasio Kabeh Utang marang Dana Pribadi OSTX|RADX: Rasio Total Utang marang Ekuitas|Adlai Nortye Ltd. - Utang Agregat marang Modal|VERU: Total Utang marang Modal|TPST - Koefisien Total Utang marang Modal|Rasio Total Utang marang Ekuitas XLO|Utang marang Ekuitas RENB|Total Utang marang Modal MURA|Total Utang marang Modal kairospharma.com (KAPA)|OnKure Therapeutics - Rasio Total Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi GDTC|Curis Corp - Total Utang marang Modal|APLM: Utang marang Ekuitas|THAR: Total Utang marang Modal|ADVB - Koefisien Total Utang marang Modal|Utang marang Ekuitas Genprex, Inc.|Utang marang Modal Calidi Bio CLDI|Rasio Total Utang marang Ekuitas SBFM (Sunshine Biopharma, Inc.)|Utang Agregat marang Modal XBIO|Total Utang marang Modal SLRX (Salarius)|Rasio Kabeh Utang marang Dana Pribadi PPBT|AON - Total Utang marang Modal|Utang marang Modal beigene.com|Checkpoint Therapeutics, Inc. (CKPT) - Utang marang Ekuitas|elevationoncology.com - Rasio Kabeh Utang marang Dana Pribadi|ICAD (iCAD Inc.) - Total Utang marang Modal|Total Utang marang Modal Ikena|Utang marang Ekuitas Notable Labs, Ltd. (NTBL)|VIRX: Utang Agregat marang Ekuitas|Total Utang marang Modal MOR (MorphoSys)|NAYA Biosciences Inc (NAYA) - Utang marang Modal|AAPGV: Rasio Total Utang marang Ekuitas